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1  | INTRODUCTION








29%-	40%	 showing	 selective	 decline	 in	 attention	 and	 psychomotor	
speed,	 and	 32%-	48%	 being	 relatively	 cognitively	 intact.6-8	 Notably,	
the	 subgroups	 with	 neurocognitive	 impairments	 present	 reduced	
functional	capacity,	more	stress	and	poorer	quality	of	life	than	patients	
who	 are	 cognitively	 intact,	 despite	 similar	 degrees	 of	 subsyndromal	










efficacy	on	cognition,	 allowance	of	non-	study	medications,	 and	 sta-
tistical	procedures	differed	between	the	studies.1,9	Such	broad	meth-
odological	 discrepancies	 provide	 the	 impetus	 for	 greater	 consensus	
in	the	field,	on	the	design	and	methodology	of	cognition	trials	 in	bi-
polar	 disorder,	 to	 optimize	 the	 chances	 of	 demonstrating	 treatment	
efficacy	on	 cognition	and	 to	 aid	 comparability	 across	 trials.	 In	 addi-







pharmacological	 interventions,	 (ii)	 a	 clinical	 recommendations	 paper	
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2  | MATERIALS AND METHODS
2.1 | The ISBD Targeting Cognition Task Force
The	 ISBD	 Targeting	 Cognition	 Task	 Force	 was	 initiated	 by	 Drs	
Miskowiak,	 Kessing,	 and	 Vieta	 and	 consisted	 of	 18	 international	




their	 expertise	 in	 cognition	 in	 bipolar	 disorder	 and	 include	 sev-
eral	members	 of	 a	 previous	 ISBD	Cognition	 Task	 Force	 led	 by	Dr	
Yatham.10







overall	 work	 timelines	 for	 accomplishing	 the	 goals	 were	 discussed,	
a	tentative	list	with	the	key	methodological	issues	in	cognition	trials	
was	reviewed	and	agreed	upon,	and	possible	solutions	to	the	issues	
were	 discussed.	 This	 was	 followed	 up	 by	 a	 telephone	 conference	
with	the	members	of	the	task	force	who	were	unable	to	attend	the	
introductory	meeting.	During	 the	call,	 the	 identified	methodological	
challenges	 and	possible	 solutions	were	 discussed	 and	 agreed	upon,	
and	additional	 challenges	were	added	 to	 the	 list.	Consensus	on	 the	
methodological	challenges	and	recommendations	with	regard	to	how	





deemed	unnecessary	 given	 a	 high	 degree	 of	 agreement	 among	 the	
members	of	the	task	force.
3  | RESULTS
3.1 | How can we enrich trials with cognitively 
impaired patients?
One-	third	to	half	of	patients	with	bipolar	disorder	do	not	show	clini-




















evidence	 from	 several	 cognition	 trials	 suggests	 that	 patients	 with	
objectively	assessed	cognitive	 impairment	have	substantially	greater	
chances	of	achieving	treatment	efficacy	on	cognition	than	those	who	
are	 non-	impaired.11,12,14-16	 While	 subjectively	 perceived	 cognitive	
difficulties	may	also	 increase	the	 likelihood	of	 treatment	efficacy	on	
cognition,	this	association	is	weak14	and	not	consistently	observed.15 
It	 therefore	 seems	 insufficient	 to	 rely	 only	 on	 patients’	 subjectively	
reported	cognitive	difficulties,	although	these	are	arguably	important	
for	 patient	 participation	 in	 trials	 and	 for	 clinical	 meaningfulness	 of	
cognition	treatments.	Indeed,	the	correlation	between	subjective	and	
objective	measures	of	 cognition	 is	poor,17,18	 indicating	 that	 it	 is	not	
always	the	patients	with	most	subjective	complaints	who	show	great-
est	objective	deficits	and	vice	versa.	This	discrepancy	seems	to	be	in-










treatment	 is	meaningful	and	 that	patients	comply	with	 trial	 require-
ments.	However,	some	patients	are	unaware	of	their	deficits	and	do	
not	 report	 them,	 but	 may	 nevertheless	 experience	 difficulties	 with	
retaining	normal	functioning	at	work	and	in	daily	life	due	to	their	cog-













plemented	 in	 this	 screening	 process.	Two	 new	 screening	 tools	with	
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documented	 sensitivity	 to	 cognitive	 impairment	 in	 bipolar	 disorder	
may	 be	 particularly	 feasible:	 (i)	 the	 self-	report	 measure	 Cognitive	
Complaints	in	Bipolar	Disorder	Rating	Assessment	(COBRA),21	for	as-
sessment	of	subjective	impairment,	and	(ii)	the	brief	neuropsycholog-












3.2 | What is a reasonable threshold for cognitive 
impairment?
There	 is	 no	 consensus	 definition	 of	 “clinically	 significant”	 cognitive	






thresholds	 should	 be	 based	 on	 single	 or	 several	 neuropsychological	




tests.	 In	 a	 secondary	 analysis	 of	 data	 from	 the	 erythropoietin	 (EPO)	
trials,	participants	with	a	score	of	≥1	SD	below	the	norm	on	at	 least	
two	cognitive	tests	had	substantially	greater	chances	of	treatment	ef-







ative	 threshold	on	 a	 global	 cognition	measure,	 such	 as	 performance	
≥0.5	SD	 below	 the	 norm.	 Indeed,	 it	 has	 been	 shown	 in	 a	 receiving	
operator	characteristic	(ROC)	analysis	of	the	SCIP	that	using	a	cut-	off	





and	practical	 recruitment	considerations	 in	 the	 individual	 trial.	While	
a	high	cut-	off	optimizes	specificity	and	 increases	statistical	power,	 it	
limits	inclusion	of	trial	participants	and	generalizability	of	the	findings.




by	 their	 premorbid	 IQ,	 educational	 level	 and	 occupational	 attain-
ment.28	Cognitive	reserve	reflects	the	capacity	of	the	brain	to	tolerate	
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patients	 to	 rule	 out	 “pseudo-	specificity”	 (i.e.,	 nonspecific	 cognitive	
improvement	due	to	treatment-	related	decrease	in	mood	symptoms).	
We	propose	euthymia	defined	as	Hamilton	Depression	Rating	Scale	




is	 logistically	 feasible,	 it	 offers	 a	more	 rigorous	method	 of	 ensuring	
the	euthymic	period	 is	stable.	However,	 it	should	be	noted	that	 the	
proposed	distinction	in	inclusion	criteria	between	euthymic	and	partly	
remitted	patients	may	be	somewhat	artificial,	since	patients	who	are	














findings).	The	 cognitive	 side	 effects	 of	 commonly	 prescribed	med-
ications	 for	 mood	 symptoms	 and	 anxiety	 are	 not	 fully	 elucidated.	
Nevertheless,	benzodiazepines	as	well	as	some	antipsychotics,	mood	
stabilizers	and	antidepressants	have	documented	cognitive	side	ef-
fects,	 partially	 due	 to	 their	 anti-	histaminergic,	 anti-	dopaminergic,	
and	anticholinergic	actions.4,5	It	is	therefore	advisable	to	avoid	high	
doses	of	concomitant	antipsychotics	and	anticholinergic	medications	











on	whether	 the	 treatment	 change	 is	merely	 a	 dose	 adjustment	 or	
commencement	of	a	new	treatment.	Concomitant	medication	should	












medical	 illness,	 current	 or	 recent	 (i.e.,	 within	 the	 past	 1-	3	months)	


















3.5 | How should efficacy on cognition be assessed?
There	 is	 a	 lack	 of	 consensus	 on	 which	 cognition	 measures	 to	 de-
fine	as	primary	outcomes	and	on	a	priori	 hierarchy	between	cogni-
tion	measures	 in	most	 trials	 in	bipolar	disorder.1	 In	 some	 instances,	
the	choice	of	the	cognitive	outcome	measure	may	be	driven	by	the	
specific	 brain	or	 cognitive	mechanisms	 that	might	be	 targeted	by	 a	
particular	agent	or	 treatment	under	study.	For	example,	 if	an	agent	
is	proposed	to	act	on	a	neurotransmitter	or	neural	system	that	sub-
serves	 a	 specific	 cognitive	 ability,	 it	may	 be	 desirable	 to	 select	 the	
primary	cognitive	outcome	based	on	this	demonstrated	link	between	
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would	have	been	collected	from	the	same	normative	population,	and	










cognitive	processing”	composites	available.	The	 task	 force	 therefore	
recommends	 that	 trials	match	 the	 neuropsychological	 tests	 in	 their	







Given	 that	 the	 ISBD-	BANC	 includes	 many	 of	 the	 MCCB	 subtests,	
there	 should	 be	 a	 reasonable	 ability	 for	 trials	 to	 include	most	 tests	
























3.6 | What is a “clinically relevant” cognitive 
improvement?
The	 lack	of	consensus	on	what	defines	a	 “clinically	 relevant”	cogni-
tive	 change	 is	 problematic	 for	 two	 reasons.	 First,	 such	 information	




correct	 a	deficit,	we	would	anticipate	effect	 sizes	equivalent	 to	 the	
known	deficits.	However,	smaller	treatment	effects	may	also	be	clini-
cally	meaningful—such	as	an	 improvement	 that	 is	half-	way	 towards	
the	normal	function	in	healthy	age-	matched	individuals.46
The	available	evidence	so	far	indicates	that	it	 is	probably	unreal-




control	groups	and	 thus	 the	magnitude	of	 the	 treatment	effects.	To	
optimize	 the	 signal	 to	noise	 ratio	 for	 cognitive	change,	 trials	 should	
implement	parallel	equivalent	 forms	of	 the	neuropsychological	 tests	
for	 the	 pre-	 and	 post-	treatment	 assessments	 if	 available.	 However,	
since	learning	effects	are	almost	impossible	to	eliminate,	it	is	of	criti-
cal	importance	to	estimate	the	“clinically	relevant”	effect	on	cognition	





measures	 of	 socio-	occupational	 function	 so	 that	 the	 impact	 of	 im-
provement	in	cognition	on	day-	to-	day	functioning	can	be	assessed.
3.7 | How should functional implications be 
evaluated?
A	major	 criticism	 of	 cognition	 trials	 has	 been	 that	 it	 is	 unclear	 from	




tion.	 Indeed,	 the	Food	and	Drug	Administration	 (FDA)	stipulates	 that	
cognition	 trials	 in	schizophrenia	must	provide	evidence	 for	 functional	








Two	 promising	 existing	 tools	 are	 the	 observer-	based	 measure,	
the	Functional	Assessment	Short	Test	(FAST),49	and	the	performance-	













Virtual	 Reality	 Functional	 Capacity	Assessment	Tool	 (VRFCAT).	This	
tool	 presents	 participants	 with	 realistic	 simulated	 environments	 to	










3.8 | When should pre- and post- assessments be 
conducted?
The	 treatment	periods	 in	RCTs	 targeting	 cognition	 range	 from	1	 to	
21	weeks	but	are	most	commonly	between	6	and	12	weeks.1,16	Short	
study	durations	have	the	benefit	of	limiting	the	confounding	effects	
of	mood	 cycling,	whereas	 longer	 trial	 durations	may	be	more	 likely	
to	 produce	 robust	 and	 enduring	 efficacy	 on	 cognition	 and	 reduce	
potential	 practice	 effects.	 The	 optimal	 duration	 of	 a	 particular	 trial	






pharmacological	 and	 other	 biological	 interventions	 for	 6-	12	weeks	





tion	 is	based	on	 (i)	 the	most	common	practice	 in	RCTs	of	biological	
and	psychological	candidate	treatments	 in	mood	disorders	targeting	
mood	symptoms	or	cognitive	impairment	and	(ii)	the	assumption	that	
the	 functional	 implications	 of	 treatment-	related	 increase	 in	 neuro-
plasticity	 would	 begin	 to	 emerge	 after	 4-	6	weeks	 and	 presumably	






person’s	 resumption	of	 habitual	 levels	 of	 daily	 activity	 and	physical	
exercise.	It	is	thus	likely	that	it	takes	time	for	objective	cognitive	im-
provement	to	translate	into	better	functioning	in	daily	life.	Preliminary	





3.9 | How should “pseudospecificity” be addressed?
Lack	 of	 control	 for	 changes	 in	 mood	 symptoms	 in	 the	 analysis	 of	


















3.10 | What are the methodological 
recommendations for specific classes of agents?
Some	 methodological	 considerations	 are	 tied	 to	 the	 properties	 of	
the	 particular	 candidate	 treatment	 under	 investigation,	 and	 there-
fore	differ	between	pro-	dopaminergic	drugs,	atypical	antipsychotics,	
anti-	inflammatory	 agents,	 and	 neuroprotective	 drugs.	 In	 particular,	












be	 investigated	 in	 an	 adjunctive	 design	 given	 some	 concern	 about	
potential	 risk	of	mania	 switch.55,56	 Such	 trials	 should	 ideally	 restrict	
recruitment	to	euthymic	patients,	given	the	antidepressant	effects	of	
these	 compounds,57,58	which	would	 confound	 the	 interpretation	 of	
potential	 cognitive	 benefits	 in	 symptomatic	 patients.	 Alternatively,	
they	 could	 include	depressed	patients	 in	 a	 head-	to-	head	 adjunctive	
8  |     MISKOWIAK et Al.






with	 relatively	 low	baseline	dopamine	 tonus	 (as	 in	euthymia).	Given	
the	drug	effects	on	dopaminergic	neurotransmission,	inclusion	of	a	re-
ward	processing	or	emotional	decision-	making	cognition	measure	as	
a	 secondary	 outcome	 could	 aid	mechanistic	 insight	 into	 the	 clinical	
effects	of	the	treatment,	as	illustrated	in	the	pramipexole	trial.59
Cognition	 trials	 investigating	 anti-	psychotic	 or	 antidepressant	
drugs	with	efficacy	on	depressive	symptoms,	such	as	lurasidone	and	
vortioxetine,	 should	 include	 euthymic	 patients	 to	 rule	 out	 pseudo-
specificity.	 Such	 trials	may	wish	 to	 include	 an	 emotional	 processing	
test	as	a	secondary	outcome	to	assess	the	mechanisms	of	treatment	
efficacy	 on	 depression.	 For	 antidepressants,	 the	 trial	 design	 should	
be	adjunctive	and	mood	state	carefully	monitored	as	antidepressant	





to	partial	 remission	 (i.e.,	allowing	 for	more	subsyndromal	depressive	
symptoms)	in	the	interest	of	recruitment	feasibility	and	generalizability	
of	 the	 findings.	For	 the	 same	 reason,	 the	 trial	 design	 should	be	ad-
junctive	and	involve	a	placebo	control	arm.	These	recommendations	
(i.e.,	 inclusion	 of	 partially	 remitted	 patients	 and	 using	 an	 adjunctive	
design	with	a	control	group)	also	apply	to	psychological	interventions	
for	cognitive	impairment	such	as	cognitive	and	functional	remediation.
3.11 | How should statistical issues around missing 
data be handled?
Strategies	 for	 handling	missing	 data	 differ	 between	 cognition	 trials	
despite	the	general	recognition	that	intention-	to-	treat	(ITT)	analyses	
should	be	 implemented	to	prevent	bias	caused	by	participant	drop-
out.	 However,	 the	 definition	 of	 ITT	 is	 vague	 and	 involves	 several	
approaches	 for	 handling	missing	 data	 in	 longitudinal	 trials.	 Last	 ob-















line,	 inclusion	of	data	 from	patients	with	only	baseline	 assessments	
will	provide	very	 limited	 information	 in	 the	 statistical	model,	 adding	










4.1 | Need for insight into the neurobiological 
targets of cognitive enhancement





lead	 to	 identification	of	 common	biomarkers	of	pro-	cognitive	 inter-
ventions.	 Specifically,	 the	 application	 of	 neuroimaging	 in	 cognition	
treatment	discovery	carries	the	potential	 to	 identify	early	change	 in	
key	neuronal	networks	that	predicts	subsequent	cognitive	 improve-
ment.	Detection	of	such	neuro-	circuitry	target	engagement	and	dose−
response	 findings	 could	 guide	 the	 development	 of	 new	mechanism	
compounds	 for	 cognitive	 impairment	 as	 a	 conceptually	 important	
middle	 step	between	 investigation	of	 such	 treatments	 in	preclinical	
models	and	large-	scale	clinical	phase	III	trials.	This	is	in	line	with	the	
National	Institutes	of	Health	(NIH)	statement	around	target	engage-
ment	 as	 a	 potential	 regulatory	 pathway.62	 Electrophysiological	 and	
psychophysiological	methods	may	also	aid	insight	into	the	neurobio-







press	 default	 mode	 network	 (DMN)	 activity	 as	 common	 neuronal	
correlates	of	cognitive	 impairment	across	distinct	neuropsychiatric	
disorders.65-72	 In	 a	 series	 of	 randomized	 placebo-	controlled	 func-
tional	magnetic	 resonance	 imaging	 (fMRI)	 studies,	a	single	dose	of	
EPO	 and	 long-	term	 EPO	 treatment	 produced	 target	 engagement	
in	 the	 dorsal	 PFC	 and	DMN	 during	 strategic	 encoding	 and	work-
ing	memory	 across	 healthy	 individuals	 and	 patients	with	 affective	
disorders,	 and	 this	 activity	 change	 correlated	 with	 cognitive	 im-
provement.73-75	Meta-	analytic	 findings	also	point	 to	an	 increase	 in	
dorsal	 prefrontal	 activity	 as	 the	most	 reliable	 marker	 of	 cognitive	
improvement	 in	response	to	cognitive	remediation	interventions	in	





revealed	 increased	 subregional	 volume	 in	 the	 left	 hippocampus	 in	
EPO-	treated	 patients,	 which	 correlated	 with	 EPO-	related	 verbal	
memory	improvement.77	Similarly,	MRI	assessment	of	an	RCT	of	cog-
nitive	 remediation	 in	 schizophrenia	 showed	 treatment-	associated	
preservation	of	 left	hippocampal	 gray	matter	volume	over	2	years,	




psychological	 interventions	 across	 several	 psychiatric	 disorders—
possibilities	that	warrant	investigation	in	future	trials.
Finally,	it	would	also	be	of	key	interest	to	include	assessments	of	
potential	blood-	based	biomarkers	 for	 cognitive	 improvements	 in	 fu-
ture	trials,	given	emerging	evidence	for	a	putative	role	of	inflammation	
and	oxidative	 stress	 in	 patients’	 cognitive	 deficits.79	 Specifically,	 as-
sessments	of	changes	in	such	biomarkers	early	in	the	course	of	treat-





Methodological recommendations for cognition trials in bipolar 
disorder by the International Society for Bipolar Disorders Targeting 






















































Methodological recommendations for cognition trials in bipolar 
disorder by the International Society for Bipolar Disorders Targeting 































10  |     MISKOWIAK et Al.
4.2 | Targeting of treatments according to patients’ 
illness stage
There	is	increasing	evidence	for	clinical	progression	in	bipolar	disor-










In	 the	 EPO	 trials,	 there	 was	 a	 small	 but	 significant	 increase	 in	








cognitive	 remediation	 is	more	effective	 in	younger,	 less	 functionally	
impaired	patients	who	use	less	antipsychotic	medication.83	Given	the	
paucity	 of	 evidence	 for	 stage-	specific	 effects	 on	 treatment	 efficacy	
on	cognition	in	bipolar	disorder,	this	question	should	be	addressed	in	
future	cognition	trials.
4.3 | Potential for a multimodal treatment approach
The	 combination	 of	 pharmacological	 and	 non-	pharmacological	 (i.e.,	
psychological	 or	 neurostimulation)	 interventions	 is	 likely	 to	 pro-
duce	 synergistic	 effects	 on	 brain	 function	 that	 translate	 into	 more	
robust	 efficacy	 on	 cognition	 than	 either	 treatment	 modality	 alone.	
Importantly,	 the	 translation	of	 treatment-	related	cognitive	 improve-







only	 maintained	 long-	term	 (≥6	months)	 in	 mice	 that	 also	 received	
continuous	cognitive	challenges.83	This	finding	is	consistent	with	the	
demonstration	 in	a	cognition	 trial	 in	unipolar	depression	 that	work-
ing	patients	displayed	greater	cognitive	benefits	of	vortioxetine	than	
those	who	were	unemployed.48	Taken	 together,	 these	observations	
are	 suggestive	of	 stronger	 treatment	effects	on	neuroplasticity	 and	
cognition	in	individuals	who	receive	continuous	cognitive	challenges.	
Multimodal	 treatment	approaches	should	therefore	be	considered	a	







are	 summarized	 in	Table	1.	Key	 recommendations	 are	 to	enrich	 tri-
als	with	cognitively	impaired	patients	by	screening	them	with	a	brief	
neuropsychological	test	battery,	to	generally	select	a	broad	cognitive	
composite	 score	 as	 the	 primary	 outcome	 and	 a	 functional	measure	





nism	 being	 targeted	 and	 the	 hypothesized	 onset	 of	 effects,	 most	
recommendations	 are	 generally	 applicable	 for	 cognition	 trials	 in	 bi-
polar	 disorder.	 Following	 these	 recommendations	 will	 increase	 the	
internal	 validity	 of	 cognition	 trials	 by	 limiting	 confounding	 factors	
and	 the	external	validity	by	ensuring	generalizability	of	 the	 findings	
and	assessment	of	 their	 translation	 to	 real-	world	outcomes.	Finally,	
neuroimaging	 and	 electrophysiological	 assessments	 in	 future	 trials	
may	 identify	 the	 neurobiological	 targets	 for	 pro-	cognitive	 interven-
tions	 that	 can	aid	 future	drug	discovery	 strategies.	 Studies	 are	 also	
warranted	to	explore	the	potential	synergistic	effects	of	multimodal	
treatment	 approaches.	 Implementing	 the	 recommendations	 is	 likely	
to	 advance	our	 understanding	of	which	 cognition	 treatments	work,	
for	whom	and	why.	Specifically,	optimizing	the	trial	design	and	meth-
odology	 across	 trials	 so	 findings	 become	more	 replicable	 and	 com-
parable	will	 advance	 the	understanding	of	which	 treatments	do—or	
do	not—improve	cognition.	While	 the	 field	 is	 still	 in	 its	 infancy,	 the	












KWM	 reports	 having	 received	 consultancy	 fees	 from	 Lundbeck	
and	 Allergan.	 KEB	 has	 served	 on	 advisory	 boards	 for	 Sunovion,	
Sumitomo	Dainippon,	Takeda-	Lundbeck,	and	Neuralstem.	AMA	has	
received	 funding	 for	 research	 projects	 and/or	 honoraria	 as	 a	 con-
sultant	 or	 speaker	 for	 the	 following	 companies	 and	 institutions:	
Otsuka,	Pfizer,	AstraZeneca,	Bristol-	Myers	Siquibb,	Lundbeck,	Brain	




Ingelheim,	 Lundbeck,	 Otsuka,	 and	 Takeda	 and	 has	 received	 grant	
money	from	Pfizer	and	Takeda.	RSM	is	a	consultant	for	and/or	re-
ceives	honorarium	for	speaking	from	Sunovian,	Johnson	&	Johnson,	
Otsuka,	 Lundbeck,	 Pfizer,	 Allergan,	 BMS,	 Shire,	 and	 Purdue.	 CLJ	
has	received	grants	from	COLCIENCIAS,	Universidad	de	Antioquia-	




Allergan,	 BMS,	 Lundbeck,	Otsuka,	 and	 Sunovion.	 IJT	 has	 received	
consultant	fees	from	Lundbeck	and	Sumitomo	Dainippon.	RJP	uses	
software	for	research	at	no	cost	from	Scientific	Brain	Training	Pro.	
TS	 has	 received	 honoraria	 for	 advisory	 board,	 consultations,	 and/
or	 speaker’s	 role	 from	Dainippon	 Sumitomo	 Pharmaceutical,	Meiji	








no	 shareholdings	 in	 pharmaceutical	 companies.	 He	 has	 conducted	
investigator-	initiated	 studies	 from	AZ,	 Eli	 Lilly	 and	 Lundbeck.	 LVK	
has	within	 the	preceding	3	 years	 been	 a	 consultant	 for	 Lundbeck,	
AstraZenica	and	Sunovion.	EV	has	received	grants,	CME-	related	hon-
oraria,	or	consulting	fees	from	Alexza,	Almirall,	AstraZeneca,	Bristol-	
Myers	 Squibb,	Cephalon,	 Eli	 Lilly,	 Ferrer,	 ForestResearch	 Institute,	
Gedeon	 Richter,	 GlaxoSmith-	Kline,	 Janssen,	 Janssen-	Cilag,	 Jazz,	
Johnson	&	Johnson,	Lundbeck,	Merch,	Novartis,	Organon,	Otsuka,	
Pfizer,	 Pierre-	Fabre,	 Qualigen,	 Roche,	 Sanofi-	Aventis,	 Schering,	
Plough,	Servier,	Shire,	Solvay,	Takeda,	Teva,	CIBERSAM,	the	Seventh	
European	 Framework	 Programme	 (ENBREC),	 the	 Stanley	 Medical	
Research	 Institute,	 United	 Biosource	 Cooperation,	 and	Wyeth.	 All	









	 1.	 Miskowiak	 KW,	 Carvalho	 AF,	 Vieta	 E,	 Kessing	 LV.	 Cognitive	 en-
hancement	 treatments	 for	 bipolar	 disorder:	 a	 systematic	 review	
and	 methodological	 recommendations.	 Eur Neuropsychopharmacol. 
2016;26(10):1541-1561.
	 2.	 Bourne	C,	Aydemir	O,	Balanza-Martinez	V,	Bora	E,	Brissos	S,	Cavanagh	





pressed,	 and	 euthymic	 states	 in	 bipolar	 disorder.	 Am J Psychiatry. 
2004;161:262-270.
	 4.	 Goldberg	JF,	Burdick	KE.	Cognitive Dysfunction in Bipolar Disorder - A 
Guide for Clinicians.	Washington,	DC:	American	Psychiatric	Publishing;	
2008.











	 9.	 Burdick	KE,	Ketter	TA,	Goldberg	JF,	Calabrese	JR.	Assessing	 cogni-
tive	function	in	bipolar	disorder:	challenges	and	recommendations	for	
clinical	trial	design.	J Clin Psychiatry.	2015;76:e342-e350.
	10.	 Yatham	 LN,	 Torres	 IJ,	 Malhi	 GS,	 Frangou	 S,	 Glahn	 DC,	 Bearden	
CE,	 et	 al.	 The	 International	 Society	 for	 Bipolar	 Disorders-	Battery	
for	 Assessment	 of	 Neurocognition	 (ISBD-	BANC).	 Bipolar Disord. 
2010;12:351-363.
	11.	 Bonnin	CM,	Reinares	M,	Martinez-Aran	A,	Balanza-Martinez	V,	Sole	
B,	Torrent	 C,	 et	 al.	 Effects	 of	 functional	 remediation	 on	 neurocog-
nitively	 impaired	 bipolar	 patients:	 enhancement	 of	 verbal	 memory.	
Psychol Med.	2015;21:1-11.
	12.	 Burdick	KE,	Braga	RJ,	Nnadi	CU,	Shaya	Y,	Stearns	WH,	Malhotra	AK.	
Placebo-	controlled	 adjunctive	 trial	 of	 pramipexole	 in	 patients	 with	
bipolar	 disorder:	 targeting	 cognitive	 dysfunction.	 J Clin Psychiatry. 
2012;73:103-112.
	13.	 Torrent	C,	Bonnin	CM,	Martinez-Aran	A,	Valle	J,	Amann	BL,	Gonzalez-
Pinto	 A,	 et	 al.	 Efficacy	 of	 functional	 remediation	 in	 bipolar	 disor-
der:	 a	 multicenter	 randomized	 controlled	 study.	 Am J Psychiatry. 
2013;170:852-859.
	14.	 Miskowiak	 KW,	 Rush	 AJ,	 Gerds	 TA,	 Vinberg	 M,	 Kessing	 LV.	
Targeting	 treatments	 to	 improve	 cognitive	 function	 in	mood	 disor-
der:	 suggestions	 from	 trials	 using	 erythropoietin.	 J Clin Psychiatry. 
2016;77:e1639-e1646.
	15.	 Ott	CV,	Vinberg	M,	Kessing	LV,	Miskowiak	KW.	The	effect	of	eryth-
ropoietin	 on	 cognition	 in	 affective	 disorders	 -	 Associations	 with	
baseline	deficits	and	change	 in	 subjective	cognitive	complaints.	Eur 
Neuropsychopharmacol.	2016;26:1264-1273.




	17.	 Demant	 KM,	 Vinberg	 M,	 Kessing	 LV,	 Miskowiak	 KW.	 Assessment	
of	 subjective	 and	 objective	 cognitive	 function	 in	 bipolar	 disorder:	
correlations,	 predictors	 and	 the	 relation	 to	 psychosocial	 function.	
Psychiatry Res.	2015;229:565-571.
	18.	 Jensen	JH,	Støttrup	MM,	Nayberg	E,	Knorr	U,	Ullum	H,	Purdon	SE,	











	21.	 Rosa	AR,	Mercade	 C,	 Sanchez-Moreno	 J,	 Sole	 B,	 Mar	 Bonnin	 CD,	
Torrent	C,	et	al.	Validity	and	reliability	of	a	rating	scale	on	subjective	
cognitive	deficits	 in	bipolar	disorder	 (COBRA).	J Affect Disord. 2013 
Aug;15(150):29-36.
	22.	 Purdon	S.	The Screen for Cognitive Impairment in Psychiatry: adminis-
tration and Psychometric Properties.	Edmonton,	Alberta,	Canada:	PNL	
Inc.; 2005.
	23.	 Guilera	 G,	 Pino	 O,	 Gomez-Benito	 J,	 Rojo	 JE,	 Vieta	 E,	 Tabares-
Seisdedos	R,	et	al.	Clinical	usefulness	of	the	screen	for	cognitive	im-
pairment	 in	psychiatry	 (SCIP-	S)	 scale	 in	patients	with	 type	 I	bipolar	
disorder.	Health Qual Life Outcomes. 2009;7:28.




	25.	 Gualtieri	 CT,	 Morgan	 DW.	 The	 frequency	 of	 cognitive	 impairment	
in	 patients	 with	 anxiety,	 depression,	 and	 bipolar	 disorder:	 an	 un-
accounted	 source	 of	 variance	 in	 clinical	 trials.	 J Clin Psychiatry. 
2008;69:1122-1130.
	26.	 Petersen	 RC,	 Stevens	 JC,	 Ganguli	 M,	 Tangalos	 EG,	 Cummings	 JL,	
DeKosky	 ST.	 Practice	 parameter:	 early	 detection	 of	 dementia:	mild	
cognitive	 impairment	 (an	 evidence-	based	 review).	 Report	 of	 the	






	28.	 Stern	 RA,	 Silva	 SG,	 Chaisson	 N,	 Evans	 DL.	 Influence	 of	 cogni-
tive	 reserve	 on	 neuropsychological	 functioning	 in	 asymptomatic	
human	 immunodeficiency	 virus-	1	 infection.	 Arch Neurol. 1996;53: 
148-153.
	29.	 Forcada	 I,	Mur	M,	Mora	E,	Vieta	E,	Bartres-Faz	D,	Portella	MJ.	The	
influence	 of	 cognitive	 reserve	 on	 psychosocial	 and	 neuropsycho-








fects	 of	 creatine	 monohydrate	 adjunctive	 therapy	 in	 patients	 with	
bipolar	depression:	results	from	a	randomized,	double-	blind,	placebo-	
controlled	trial.	J Affect Disord.	2016;pii:S0165-0327	32114-0.







pituitary-adrenal	axis	function	 in	patients	with	bipolar	disorder.	Br J 
Psychiatry.	2004;184:496-502.
	36.	 Pavlova	B,	Perlis	RH,	Alda	M,	Uher	R.	Lifetime	prevalence	of	anxiety	





	38.	 Watson	 S,	 Gallagher	 P,	 Porter	 RJ,	 Smith	MS,	 Herron	 LJ,	 Bulmer	 S,	




Improvements	 in	 neurocognitive	 function	 and	 mood	 following	 ad-
junctive	 treatment	 with	 mifepristone	 (RU-	486)	 in	 bipolar	 disorder.	
Neuropsychopharmacology.	2004;29:1538-1545.
	40.	 Miskowiak	KW,	Ehrenreich	H,	Christensen	EM,	Kessing	LV,	Vinberg	M.	
Recombinant	 human	erythropoietin	 to	 target	 cognitive	 dysfunction	
in	 bipolar	 disorder:	 a	 double-	blind,	 randomized,	 placebo-	controlled	
phase	2	trial.	J Clin Psychiatry.	2014;75:1347-1355.
	41.	 Burdick	 KE,	 Goldberg	 TE,	 Cornblatt	 BA,	 Keefe	 RS,	 Gopin	 CB,	
Derosse	 P,	 et	 al.	The	MATRICS	 consensus	 cognitive	 battery	 in	 pa-
tients	 with	 bipolar	 I	 disorder.	 Neuropsychopharmacology. 2011;36: 
1587-1592.
	42.	 Sperry	 SH,	 O’Connor	 LK,	 Ongur	 D,	 Cohen	 BM,	 Keshavan	 MS,	
Lewandowski	 KE.	 Measuring	 cognition	 in	 bipolar	 disorder	 with	
psychosis	 using	 the	 MATRICS	 consensus	 cognitive	 battery.	 J Int 
Neuropsychol Soc.	2015;21:468-472.
	43.	 Van	Rheenen	TE,	Rossell	SL.	An	empirical	evaluation	of	the	MATRICS	
consensus	 cognitive	 battery	 in	 bipolar	 disorder.	 Bipolar Disord. 
2014;16:318-325.
	44.	 Fulford	 D,	 Peckham	 AD,	 Johnson	 K,	 Johnson	 SL.	 Emotion	 per-
ception	 and	 quality	 of	 life	 in	 bipolar	 I	 disorder.	 J Affect Disord. 
2014;152–154:491-497.
	45.	 Hoertnagl	CM,	Biedermann	F,	Yalcin-Siedentopf	N,	Muehlbacher	M,	
Rauch	AS,	Baumgartner	 S,	 et	 al.	 Prosodic	 and	 semantic	 affect	 per-







A	 summary	 of	 the	 FDA-	NIMH-	MATRICS	workshop	 on	 clinical	 trial	
design	 for	 neurocognitive	 drugs	 for	 schizophrenia.	 Schizophr Bull. 
2005;31(1):5-19.
	48.	 McIntyre	RS,	Florea	I,	Tonnoir	B,	Loft	H,	Lam	RW,	Christensen	MC.	
Efficacy	 of	 vortioxetine	 on	 cognitive	 functioning	 in	 working	 pa-




Short	Test	(FAST)	in	bipolar	disorder.	Clin Pract Epidemiol Ment Health. 
2007;3:5.





M,	 et	 al.	 Validation	 of	 a	 computerized	 test	 of	 functional	 capacity.	
Schizophr Res.	2016;175:90-96.
	52.	 Kaser	 M,	 Deakin	 J,	 Michael	 A,	 Zapata	 C,	 Bansal	 R,	 Ryan	 D,	 et	 al.	
Modafinil	 improves	 episodic	 memory	 and	 working	 memory	 cogni-
tion	 in	 patients	with	 remitted	 depression:	 a	 double-	blind,	 random-
ized,	 placebo-	controlled	 study.	 Biological Psychiatry CNNI. 2017; 
2:115-122.
	53.	 Aimone	 JB,	 Wiles	 J,	 Gage	 FH.	 Potential	 role	 for	 adult	 neuro-








     |  13MISKOWIAK et Al.
	56.	 Malhi	GS,	Byrow	Y,	Bassett	D,	Boyce	P,	Hopwood	M,	Lyndon	W,	et	al.	
Stimulants	 for	depression:	on	 the	up	and	up?	Aust N Z J Psychiatry. 
2016;50:203-207.
	57.	 Corp	SA,	Gitlin	MJ,	Altshuler	 LL.	A	 review	of	 the	use	of	 stimulants	
and	 stimulant	 alternatives	 in	 treating	 bipolar	 depression	 and	major	
depressive	disorder.	J Clin Psychiatry.	2014;75:1010-1018.
	58.	 Fawcett	 J,	 Rush	AJ,	Vukelich	 J,	Diaz	 SH,	Dunklee	 L,	 Romo	P,	 et	 al.	




ences	 on	 emotional	 decision	 making	 in	 euthymic	 bipolar	 patients.	
Neuropsychopharmacology.	2014;39:274-282.
	60.	 Maud	C.	Vortioxetine	 in	 bipolar	 depression	 induces	 a	mixed/manic	
switch.	Australas Psychiatry.	2016;24:206-207.




M,	 Rabey	 JM.	 Quantitative	 EEG	 after	 brain	 stimulation	 and	






	64.	 Dietsche	 B,	 Backes	 H,	 Stratmann	M,	 Konrad	 C,	 Kircher	 T,	 Krug	A.	













	68.	 Minzenberg	 MJ,	 Laird	 AR,	 Thelen	 S,	 Carter	 CS,	 Glahn	 DC.	 Meta-	
analysis	of	41	functional	neuroimaging	studies	of	executive	function	
in	schizophrenia.	Arch Gen Psychiatry.	2009;66:811-822.




	70.	 Ragland	 JD,	 Laird	AR,	 Ranganath	 C,	 Blumenfeld	 RS,	 Gonzales	 SM,	




memory	 task	 in	 manic,	 euthymic	 and	 depressed	 bipolar	 subjects.	
Psychiatry Res.	2010	Apr;30(182):22-29.
	72.	 Miskowiak	K,	O’Sullivan	U,	Harmer	CJ.	Erythropoietin	enhances	hip-
pocampal	 response	 during	memory	 retrieval	 in	 humans.	 J Neurosci. 
2007	Mar;14(27):2788-2792.





PJ,	 et	 al.	 Effects	 of	 erythropoietin	 on	 emotional	 processing	 bi-
ases	 in	 patients	with	major	 depression:	 an	 exploratory	 fMRI	 study.	
Psychopharmacology.	2009;207:133-142.
	75.	 Ramsay	 IS,	 MacDonald	 AW	 III.	 Brain	 correlates	 of	 cognitive	 re-
mediation	 in	 schizophrenia:	 activation	 likelihood	 analysis	 shows	
preliminary	 evidence	 of	 neural	 target	 engagement.	 Schizophr Bull. 
2015;41:1276-1284.













	80.	 Grande	 I,	 Berk	 M,	 Birmaher	 B,	 Vieta	 E.	 Bipolar	 disorder.	 Lancet. 
2016;387:1561-1572.
	81.	 Vieta	E,	Reinares	M,	Rosa	AR.	Staging	bipolar	disorder.	Neurotox Res. 
2011;19:279-285.
	82.	 Vita	A,	Deste	G,	de	PL,	Barlati	S,	Poli	R,	Cesana	BM,	et	al.	Predictors	
of	 cognitive	 and	 functional	 improvement	 and	 normalization	 after	
cognitive	 remediation	 in	patients	with	 schizophrenia.	Schizophr Res. 
2013;150:51-57.




How to cite this article:	Miskowiak	KW,	Burdick	KE,	Martinez-
Aran	A,	et	al.	Methodological	recommendations	for	cognition	
trials	in	bipolar	disorder	by	the	International	Society	for	
Bipolar	Disorders	Targeting	Cognition	Task	Force.	Bipolar 
Disord. 2017;00:1–13. https://doi.org/10.1111/bdi.12534
